432 related articles for article (PubMed ID: 28885612)
21. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Agrusa JE; Egress ER; Lowe EJ
Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
[TBL] [Abstract][Full Text] [Related]
22. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
23. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
Scott LJ
Drugs; 2017 Mar; 77(4):435-445. PubMed ID: 28190142
[TBL] [Abstract][Full Text] [Related]
24. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
Berger GK; McBride A; Lawson S; Royball K; Yun S; Gee K; Bin Riaz I; Saleh AA; Puvvada S; Anwer F
Crit Rev Oncol Hematol; 2017 Jan; 109():42-50. PubMed ID: 28010897
[TBL] [Abstract][Full Text] [Related]
25. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
27. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
[TBL] [Abstract][Full Text] [Related]
28. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
Nizamuddin I; Galvez C; Pro B
Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
[TBL] [Abstract][Full Text] [Related]
29. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Alperovich A; Younes A
Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.
Zinzani PL; Corradini P; Gianni AM; Federico M; Santoro A; Vitolo U; Barosi G; Tura S
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):507-13. PubMed ID: 26195435
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.
Gibb A; Jones C; Bloor A; Kulkarni S; Illidge T; Linton K; Radford J
Haematologica; 2013 Apr; 98(4):611-4. PubMed ID: 23065511
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Vaklavas C; Forero-Torres A
Ther Adv Hematol; 2012 Aug; 3(4):209-25. PubMed ID: 23606932
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
[TBL] [Abstract][Full Text] [Related]
36. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
38. Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy.
Sotomayor EM; Young KH; Younes A
Clin Adv Hematol Oncol; 2014 Apr; 12(4 Suppl 10):1-22. PubMed ID: 24870054
[TBL] [Abstract][Full Text] [Related]
39. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
Han TH; Chen R; Advani R; Berryman RB; Smith SE; Forero-Torres A; Rosenblatt JD; Smith MR; Zain J; Hunder NN; Engert A
Cancer Chemother Pharmacol; 2013 Jul; 72(1):241-9. PubMed ID: 23719719
[TBL] [Abstract][Full Text] [Related]
40. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
Bhatt S; Ashlock BM; Natkunam Y; Sujoy V; Chapman JR; Ramos JC; Mesri EA; Lossos IS
Blood; 2013 Aug; 122(7):1233-42. PubMed ID: 23838350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
